# Thermal ablation for pulmonary oligometastases from hepatocellular carcinoma: initial experience and retrospective study

## TL;DR

This study shows that thermal ablation is a safe and effective treatment for lung metastases from liver cancer, with survival outcomes influenced by initial cancer stage and treatment strategies.

## Contribution

The study provides initial evidence on the long-term efficacy of thermal ablation for pulmonary metastases from hepatocellular carcinoma.

## Key findings

- Thermal ablation achieved 100% technical success and 96.8% technical efficacy for treating pulmonary metastases.
- Median progression-free survival was 11.4 months, and median overall survival was 33.0 months.
- Radical treatment for primary HCC and early BCLC stage were significant predictors of better survival outcomes.

## Abstract

To evaluate the long-term efficacy of thermal ablation in the treatment of pulmonary oligometastases (POs) from hepatocellular carcinoma (HCC) and to explore the prognosis-related influencing factors.

From October 2012 to January 2019, 145 POs (mean diameter: 2.3 cm, ≤ 4 POs per patient) in 62 patients (male = 33, female = 29, mean age: 61.0 years old) with HCC were treated by thermal ablation. The primary endpoints were progression-free survival (PFS) and overall survival (OS), and the secondary endpoints were technical success, technical efficacy, and complications. PFS and OS were analyzed by the log-rank test and Cox proportional hazards regression models.

Technical success, technical efficacy and major complications were 100, 96.8, and 21%, respectively. During the median follow-up of 30 months (range: 16–50), the median PFS was 11.4 months (95% CI 10.1–12.8), the 1- and 2-year PFS rates were 43.5 and 10.2%, respectively, and radical treatments for primary HCC (P < 0.01), metachronous POs (P < 0.01) and initial Barcelona Clinic Liver Cancer (BCLC) stage 0-B (P < 0.05) were significant indicators of superior PFS. The mOS was 33.0 months (95% CI 26.9–39.1), and the 1-, 2- and 3-year OS rates were 98.4, 78.7% and 43.7%, respectively. Radical treatments for primary HCC (P < 0.01) and initial BCLC stage 0-B (P < 0.05) showed superior OS.

POs ablation after primary HCC control is safe and effective, and initial BCLC stage evaluation and radical treatment strategies should be emphasized. This study has certain limitations, including the retrospective design, single-center data, selection bias and small sample size.